---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-010633"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2026-02-05T23:59:59+00:00"
generated_at: "2026-05-16T04:22:56.612353+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q4 net loss $0.29/shr; SOL-1 data readout at Macula Society Feb 25-28

## Summary
- Q4 2025 net revenue $13.3M, down 22.4% YoY; full year $52.0M, down 18.5%.
- Net loss Q4 $64.7M ($0.29/shr), full year $265.9M ($1.42/shr); R&D spend rose to $50.8M.
- SOL-1 Phase 3 wet AMD superiority data to be presented at Macula Society meeting Feb 25-28, 2026.
- Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1, pending positive results and FDA interactions.
- Cash $737.1M as of Dec 31, 2025; raised $475M in Sep 2025 equity offering; runway into 2028.

## SEC filing metadata
- accession: 0001104659-26-010633
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2026-02-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/0001104659-26-010633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/tm265061d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-010633
- JSON: https://secwatch.observer/filing/0001104659-26-010633.json
- Plain text: https://secwatch.observer/filing/0001104659-26-010633.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.